ATE319449T1 - Dosierschema für ppar-gamma-aktivatoren - Google Patents

Dosierschema für ppar-gamma-aktivatoren

Info

Publication number
ATE319449T1
ATE319449T1 AT02805961T AT02805961T ATE319449T1 AT E319449 T1 ATE319449 T1 AT E319449T1 AT 02805961 T AT02805961 T AT 02805961T AT 02805961 T AT02805961 T AT 02805961T AT E319449 T1 ATE319449 T1 AT E319449T1
Authority
AT
Austria
Prior art keywords
ppar
dosage scheme
gamma
gamma activators
administration
Prior art date
Application number
AT02805961T
Other languages
English (en)
Inventor
Kathleen Keating Brown
Philip G Baer
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE319449T1 publication Critical patent/ATE319449T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02805961T 2001-12-21 2002-12-18 Dosierschema für ppar-gamma-aktivatoren ATE319449T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34515301P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
ATE319449T1 true ATE319449T1 (de) 2006-03-15

Family

ID=23353763

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02805961T ATE319449T1 (de) 2001-12-21 2002-12-18 Dosierschema für ppar-gamma-aktivatoren

Country Status (8)

Country Link
US (1) US20050107450A1 (de)
EP (1) EP1465627B1 (de)
JP (1) JP2005514399A (de)
AT (1) ATE319449T1 (de)
AU (1) AU2002367154A1 (de)
DE (1) DE60209824T2 (de)
ES (1) ES2259736T3 (de)
WO (1) WO2003055485A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR052888A1 (es) * 2005-01-28 2007-04-11 Lilly Co Eli Uso del agonista alfa de ppar para preparar una formulacion farmaceutica, paquete y dosis unitaria de dicha formulacion
AU2008248186B2 (en) 2007-05-07 2014-02-06 Merck Sharp & Dohme Corp. Method of treatment using fused aromatic compounds having anti-diabetic activity
ES2678046T3 (es) 2014-04-02 2018-08-08 Minoryx Therapeutics S.L. Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central
EP4194001B1 (de) * 2015-04-22 2026-03-18 Cedars-Sinai Medical Center Enterisch verabreichte bittere oligopeptide zur behandlung von typ-2-diabetes und fettleibigkeit
LT3548026T (lt) 2016-12-01 2021-05-25 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dionas nealkoholinio kepenų suriebėjimo gydymui
US20180153860A1 (en) * 2016-12-02 2018-06-07 T3D Therapeutics, Inc. Methods of dose administration for treating or preventing cognitive impairment using indane acetic acid derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
ATE372782T1 (de) * 1999-06-21 2007-09-15 Lilly Co Eli Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin- abhängigen diabetes

Also Published As

Publication number Publication date
WO2003055485A1 (en) 2003-07-10
US20050107450A1 (en) 2005-05-19
DE60209824D1 (de) 2006-05-04
EP1465627A1 (de) 2004-10-13
EP1465627B1 (de) 2006-03-08
AU2002367154A1 (en) 2003-07-15
JP2005514399A (ja) 2005-05-19
DE60209824T2 (de) 2006-10-19
ES2259736T3 (es) 2006-10-16

Similar Documents

Publication Publication Date Title
TW200602324A (en) Tetrahydro-indazole cannabinoid modulators cross reference to related applications
MY135222A (en) Substituted phenylacetamides and their use as glucokinase activators
BR0212203A (pt) Composições e processos para tratamento de diabetes
SG130189A1 (en) Substituted indole-o-glucosides
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
MXPA03010201A (es) Derivados de 2-piridin-ciclohexan-1,4-diamina sustituidos.
GB0222495D0 (en) Compounds
UA86599C2 (en) Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides
DE60233655D1 (de) R und retinoid x rezeptorenmodulatoren
BR0317494A (pt) Pré-polìmeros de poliuretano bloqueados com cetonas cìclicas ch-ácidas, sistemas reativos preparados a partir dos mesmo, sua preparação e aplicação
DE69941435D1 (de) Monoclonaler anti-heparanase antikörper zur neutralisierung der heparanaseaktivität
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
LT2004074A (en) Matricines metalproteinazes inhibuojanti kompozicija neoplazinems ligoms gydyti
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
MX2007004765A (es) Compuestos y metodos que modulan la actividad de la trombopoyetina.
DE602005026276D1 (de) Myricitrin verbindungen zur behandlung von schlafstörungen
ATE319449T1 (de) Dosierschema für ppar-gamma-aktivatoren
DE602004031954D1 (de) Verbindungen zur behandlung von stoffwechselstörungen
ATE358501T1 (de) Zubereitung für die wundheilung und zur verhinderung des anhaftens von verbänden an die wunde
TW200604149A (en) Norbornane based cycloaliphatic compounds containing nitrile groups
MXPA04000446A (es) 4-aminociclohexanoles sustituidos.
SE0200198D0 (sv) New use
ATE402694T1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
NO20033413L (no) Krystallmodifisering av et syklisk depsipeptid med forbedret aktivitet

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties